CI

At a glance

ClinicalIndex Comparison Record
Phase 3Active· 187 enrolled
Drug / intervention
Cabozantinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03690388
NCT03690388Phase 3Active
CompareCT.gov

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

Exelixis·interventional·Posted Oct 1, 2018·Updated Sep 25, 2025

In Brief

A Phase 3 clinical trial evaluating Cabozantinib and Placebo for Differentiated Thyroid Cancer. Active but no longer recruiting, targeting 187 participants across 164 sites in 25 countries.

Detailed Summary

The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine-Refractory Differentiated Thyroid Cancer (DTC) who have progressed after prior vascular endothelial growth factor receptor (VEGFR)-Targeted therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDifferentiated Thyroid Cancer
CountriesArgentina, Australia, Austria, Belgium, Brazil, Canada, Croatia, Czechia, France, Germany, Hong Kong, Hungary, Israel, Italy, Mexico, Netherlands, Poland, Romania, Russia, South Korea, Spain, Taiwan, Thailand, United Kingdom, United States
CollaboratorsIpsen

Timeline

Phase 3Active
20192020202120222023202420252026
First PostedOct 1, 2018
Enrollment StartOct 5, 2018
Primary CompletionAug 19, 2020
Study CompletionJul 31, 2026
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 7.8 years ago

Interventions

Cabozantinibdrug

Tablets containing 60-mg or 20-mg cabozantinib once daily orally.

Placebodrug

Tablets containing placebo equivalent of 60-mg or 20-mg cabozantinib once daily orally.